IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.979
AS - Asia 4.843
EU - Europa 3.784
SA - Sud America 1.006
AF - Africa 131
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 7
Totale 23.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.824
SG - Singapore 2.160
UA - Ucraina 1.177
CN - Cina 1.102
BR - Brasile 787
DE - Germania 633
HK - Hong Kong 539
FI - Finlandia 445
IT - Italia 377
VN - Vietnam 363
RU - Federazione Russa 287
SE - Svezia 256
FR - Francia 194
IE - Irlanda 190
TR - Turchia 138
IN - India 107
GB - Regno Unito 88
CA - Canada 87
AR - Argentina 82
KR - Corea 63
IQ - Iraq 56
BD - Bangladesh 55
CO - Colombia 38
MX - Messico 38
ZA - Sudafrica 35
ID - Indonesia 33
EC - Ecuador 30
IR - Iran 28
MA - Marocco 28
PK - Pakistan 26
JP - Giappone 25
ES - Italia 22
BE - Belgio 21
PH - Filippine 21
SA - Arabia Saudita 21
VE - Venezuela 21
UZ - Uzbekistan 15
EU - Europa 14
MY - Malesia 14
NL - Olanda 13
TN - Tunisia 13
PY - Paraguay 12
KE - Kenya 11
UY - Uruguay 11
CL - Cile 10
JO - Giordania 10
PL - Polonia 10
AT - Austria 9
PE - Perù 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
PS - Palestinian Territory 7
AL - Albania 6
AU - Australia 6
DO - Repubblica Dominicana 6
EG - Egitto 6
ET - Etiopia 6
NP - Nepal 6
RO - Romania 6
AZ - Azerbaigian 5
BO - Bolivia 5
JM - Giamaica 5
KZ - Kazakistan 5
RS - Serbia 5
BH - Bahrain 4
HN - Honduras 4
LB - Libano 4
LT - Lituania 4
SN - Senegal 4
AO - Angola 3
BA - Bosnia-Erzegovina 3
GA - Gabon 3
GE - Georgia 3
GR - Grecia 3
IL - Israele 3
KG - Kirghizistan 3
KH - Cambogia 3
LV - Lettonia 3
NI - Nicaragua 3
PA - Panama 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
GT - Guatemala 2
HU - Ungheria 2
LU - Lussemburgo 2
MD - Moldavia 2
OM - Oman 2
PR - Porto Rico 2
TG - Togo 2
TH - Thailandia 2
TZ - Tanzania 2
AN - Antille olandesi 1
BJ - Benin 1
BN - Brunei Darussalam 1
Totale 23.742
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.143
Ashburn 1.010
Ann Arbor 968
Singapore 815
Jacksonville 768
Seattle 713
Wilmington 677
Cambridge 617
Chandler 543
Beijing 541
Hong Kong 536
Dearborn 503
San Jose 286
Boardman 236
Princeton 197
Dublin 191
Lauterbourg 168
Munich 162
Udine 131
Los Angeles 129
Ho Chi Minh City 120
Izmir 112
Dallas 105
San Diego 94
Helsinki 78
São Paulo 76
Buffalo 75
Hanoi 72
New York 69
Hefei 66
Redondo Beach 59
Seoul 56
Ogden 47
The Dalles 45
Des Moines 44
Santa Clara 43
Nanjing 37
Norwalk 36
Ottawa 35
Turku 29
Kunming 28
Rio de Janeiro 27
Dong Ket 25
Florence 25
Mumbai 24
Orem 23
Tokyo 22
Baghdad 20
Johannesburg 20
Brussels 19
Guangzhou 19
Montreal 19
Andover 17
Curitiba 17
Trieste 17
Council Bluffs 16
Saint Petersburg 16
Belo Horizonte 15
Boston 15
Atlanta 14
Haiphong 14
Jinan 14
Nuremberg 14
Shanghai 14
Shenyang 14
Da Nang 13
Frankfurt am Main 13
Bogotá 12
Dhaka 12
Falls Church 12
Leawood 12
Tashkent 12
Toronto 12
Brasília 11
Chennai 11
Lappeenranta 11
Nanchang 11
Poplar 11
Quito 11
San Mateo 11
Stockholm 11
Amman 10
Mexico City 10
Porto Alegre 10
Warsaw 10
Ardabil 9
Brooklyn 9
Phoenix 9
Recife 9
Salvador 9
San Francisco 9
Cape Town 8
Chengdu 8
Denver 8
Fortaleza 8
Goiânia 8
Grafing 8
Guarulhos 8
Totale 15.991
Salva come PNG Salva come JPEG
Nome #
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 236
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 209
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 205
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 198
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 195
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 191
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 185
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 178
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 173
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 172
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 171
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 170
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 169
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 167
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 166
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 166
Management of immune thrombocytopenia in elderly patients 164
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 163
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 163
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 163
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 161
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 161
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 160
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 159
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 159
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 158
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 154
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 154
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 153
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 153
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 153
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 152
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 152
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 151
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 150
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 148
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 147
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 147
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 147
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 147
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 146
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 145
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 145
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 145
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 144
Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing? 144
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 144
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 144
Rituximab for the treatment of type II mixed cryoglobulinemia 142
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 142
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 141
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 141
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 139
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 138
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 137
The role of Rituximab in the therapy of mixed cryoglobulinemia 137
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 137
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 136
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 136
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 135
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 135
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 135
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 134
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 134
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 134
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 134
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 133
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 133
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 133
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 133
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 132
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 132
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 131
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 131
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 131
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 131
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 131
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 130
Rituximab-responsive CIDP. 130
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 129
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 129
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults. 128
A retrospective analysis of 144 patients with aggressive non-Hodgkin's lymphoma: impact of aurtologoaus stem cell transplantation in first remission on autcome 128
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 128
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 127
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. 126
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. 126
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 126
Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin’s lymphomas 125
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 125
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 125
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 124
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 124
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 123
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. 123
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 123
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 122
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. 122
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 122
High dose therapy with stem cell rescue in elderly atients with aggressive poor risk lymphomas: a review of 14 cases. 121
Totale 14.631
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021591 0 0 0 0 0 0 0 0 0 119 300 172
2021/20221.580 57 183 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/20253.199 52 252 154 66 120 168 214 204 342 261 466 900
2025/20265.031 378 649 501 523 825 451 689 186 430 399 0 0
Totale 24.223